Compugen Ltd (CGEN): Cash & Equivalents
$90.60M
As of 2025-12-31
+101.6%
3-year compound annual growth
+66.2%
5-year compound annual growth
+23.7%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $90.60M | +397.0% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $18.23M | +31.2% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $13.89M | +25.6% | 2026-03-02, Balance as of period end |
| 2022-12-31 | $11.06M | +41.8% | 2025-03-04, Balance as of period end |
| 2021-12-31 | $7.80M | +9.2% | 2024-03-05, Balance as of period end |
| 2020-12-31 | $7.14M | -22.2% | 2023-08-23, Balance as of period end |
| 2019-12-31 | $9.19M | +56.7% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $5.86M | -77.0% | 2021-02-25, Balance as of period end |
| 2017-12-31 | $25.47M | +162.3% | 2019-03-21, Balance as of period end |
| 2016-12-31 | $9.71M | -9.9% | 2018-03-27, Balance as of period end |
| 2015-12-31 | $10.78M | -58.0% | 2017-02-16, Balance as of period end |
| 2014-12-31 | $25.64M | -10.8% | 2017-02-16, Balance as of period end |
| 2013-12-31 | $28.75M | +75.6% | 2016-03-07, Balance as of period end |
| 2012-12-31 | $16.37M | +180.1% | 2015-03-12, Balance as of period end |
| 2011-12-31 | $5.85M | -19.9% | 2014-02-18, Balance as of period end |
| 2010-12-31 | $7.30M | -51.8% | 2013-03-21, Balance as of period end |
| 2009-12-31 | $15.14M | n/a | 2012-03-14, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Compugen Ltd (CGEN) | 2025-12-31 | $90.60M | +397.0% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $743.29M | +25.1% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $104.13M | -54.2% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $20.99M | -42.4% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $232.19M | +4.1% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $65.93M | -36.4% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $60.24M | -59.7% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $226.69M | +226.9% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $14.68M | -25.7% |
Compare CGEN, RXRX, AUTL, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗